

## Lung Cancer Focused Molecular Profiling Panels

- I. Lung cancer focused molecular profiling panels are considered **medically necessary** when:
  - A. The member has a diagnosis of:
    1. Advanced (stage IIIb or higher) or metastatic lung adenocarcinoma, **OR**
    2. Advanced (stage IIIb or higher) or metastatic large cell lung carcinoma, **OR**
    3. Advanced (stage IIIb or higher) or metastatic squamous cell lung carcinoma, **OR**
    4. Advanced (stage IIIb or higher) or metastatic non-small cell lung cancer (NSCLC) not otherwise specified (NOS), **AND**
  - B. The member is seeking further cancer treatment (e.g., therapeutic chemotherapy).
- II. Repeat lung cancer-focused molecular profiling panels are considered **medically necessary** when the member has progression on targeted therapy for non-small cell lung cancer.
- III. Lung cancer-focused molecular profiling panels are considered **investigational** for all other indications.

**NOTE:** If a panel is performed, appropriate panel codes should be used.

## DEFINITIONS

1. **Advanced** cancer (advanced stages or advanced tumor or advanced/metastatic): Cancer that is unlikely to be cured or controlled with

treatment. The cancer may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body. Treatment may be given to help shrink the tumor, slow the growth of cancer cells, or relieve symptoms.

## REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2025. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf)